ONE MIND has numerous projects at various stages of development. The following are our flagship initiatives, which have been in development for over a year and are positioned for full operational launch in 2013.
GEMINI is a Public-Private Partnership combining best-in-class science, technology, and expertise. One Mind is catalyzing collaboration between international research centers of excellence, industry, and government to accelerate the translation of basic science into breakthrough diagnostics and improved treatments for TBI & PTS.
TBI affects an estimated 10 million people worldwide and more than 1.7 million in the U.S. every year. TBI is a silent epidemic – its symptoms are frequently invisible, thus difficult to diagnose and treat. TBI can lead to motor, cognitive, and social impairments that interfere with an individual’s ability to be productive. Gemini will accelerate advancements in diagnosis and treatment for veterans and civilians alike. Service members and veterans account for only 1% of TBI cases in the United States each year.
PTS is a severe anxiety disorder that follows an experience causing psychological trauma. Early evidence suggests that as many as 20% of the approximately 1.64 million U.S. troops returning from deployments to Afghanistan and Iraq show symptoms of PTS or major depression, making PTS the most common serious injury of these wars. It is also estimated that 8% of Americans will, in their lifetime, experience PTS from a traumatic event (e.g., sexual assault, domestic violence, crime victims, severe storms, first responders to violent crime).
In 2013, One Mind will launch this multi-country, multi-site initiative to create a large-scale database of individuals with acute head trauma and/or psychological trauma with rigorous biomarker (e.g., genetics, imaging) and clinical measures to:
One Mind has joined the Orion Bionetworks Alliance for Multiple Sclerosis. Orion is a program of the Marin Community Fund, a non-profit 501(c)(3) corporation. Orion Bionetworks is a multidisciplinary computational modeling community that harnesses the power of data, technology, and collaboration to pave the way for Systems Medicine and transform the research and treatment of multiple sclerosis and other brain disorders.
Orion Bionetworks Mission
We are developing causal disease models with unprecedented predictive power that will drive progress towards better treatments and, ultimately, cures for multiple sclerosis and other devastating brain disorders.
To advance the understanding of brain disorders, Orion Bionetworks is building powerful, data-driven disease models.
A unique cooperative alliance model enables sustainable, multidisciplinary collaboration.
PHASE I: The initial program integrates clinical, biomarker and imaging data from existing databases of over 7,000 patients into a first-generation causal MS disease model. Program partners: Accellerated Cure Project for MS; Brigham Women’s Hospital, GNS Healthcare; MetaCell; PatientsLikeMe. Funding Partner: Janssen Pharmaceutical Research. This phase successfully launched in January of 2013.
PHASE II: Use combined, prospectively collected imaging, biomarker and deep phenotypic data from an additional 2000-3000 patients.
PHASE III: Model 3.0 will be focused on identifying response biomarkers to MS treatments.
ALZHEIMER’S DISEASE & DEMENTIA. We are, in cooperation with numerous partners, developing a comprehensive strategy to advance research in Alzheimer’s and dementia, two diseases that impose a rapidly growing burden on millions.
THE ALZHEIMER’S DISEASE AND DEMENTIA LEADERSHIP COUNCIL (ADDLC). The ADDLC was launched in November 2011 in partnership with the New York Academy of Sciences (NYAS) and has formed four working groups focused on Basic Research, Early Development and Translational Research, Prevention Trials, and Policy for Public Private Partnerships. This collective effort will drive recommendations for a global strategy and Program for AD and Dementia.
BRAIN CANADA. One Mind has also established a partnership with Brain Canada, wherein jointly prioritized programs in the Global Brain Disorders Strategic Roadmap will be funded by both organizations. Brain Canada has federal budget commitments of $100 million to match private funding for brain research.
GUARDIAN ANGELS ZERO POWER BIOSENSORS. ONE MIND and the Europe-based Guardian Angels For Smarter Life (“GA”) are allied to design research projects in North America using the revolutionary GA Zero Power Biosensors. Their potential for analysis, monitoring and treatment of major brain diseases will revolutionize brain science. An early goal of this alliance is to enable monitoring of the evolution of the Alzheimer’s. These biosensors will establish a thorough understanding of the disease’s progression on physical and bio-chemical processes in the body thereby determining how they affect the quality of life of the patient.
EDUCATION AND OUTREACH. We are drafting a strategic plan for expanding public awareness and understanding of brain disorders and injuries in order to eliminate the stigma, shame, and discrimination associated with mental illness. The campaign, which will launch in 2013, will include PSA’s, print advertising, social media, radio and television, and the internet.